BOURNER, Josephine; VAILLANT, Michel; ABDEL SALAM, Alex Paddy; JASPARD, Marie; FRITZELL, Camille; JACOB, Shevin T; FLETCHER, Tom E; RAMHARTER, Michael; AJAYI, Nnennaya; OKOGBENIN, Sylvanus; ERAMEH, Cyril; GRANT, Donald; SAMUELS, Robert; AYODEJI, Oladele Oluwafemi; SPRECHER, Armand; GONCALVES, Bronner P; EDWARDS, Tansy; OLLIARO, Piero; DUVIGNAUD, Alexandre; FRITZELL, Camille; MALVY, Denis

doi:10.3201/eid3102.240251

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

BOURNER, Josephine

VAILLANT, Michel

ABDEL SALAM, Alex Paddy

Idioma

Article de revue

Este ítem está publicado en

Emerging Infectious Diseases. 2025-02-01, vol. 31, n° 2, p. 9-16

Resumen en inglés

The current recommendation for treating Lassa fever with ribavirin is supported only by weak evidence. Given the persistent effects in areas with endemic transmission and epidemic potential, there is an urgent need to reassess ribavirin and investigate other potential therapeutic candidates; however, a robust clinical trial method adapted to Lassa fever epidemiology has not yet been established. We propose an adaptive phase II/III multicenter randomized controlled platform trial that uses a superiority framework with an equal allocation ratio and accounts for challenges selecting the primary end point and estimating the target sample size by using an interim analysis.< Leer menos

Palabras clave en inglés

Lassa Fever

Clinical Trials

Phase II/III Multicenter Randomized Controlled Platform Trial

Viruses

Metadatos

Compartir este ítem

Licencia de uso del documento

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación